Drug intelligence / Profile preview

Rincell-2

Development stage: Preclinical
Lead developer: Rinri Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Otic

Overview

Rincell-2 is an off-the-shelf cell therapy being developed by Rinri Therapeutics for the treatment of sensorineural hearing loss. It consists of induced pluripotent stem cell-derived human otic neuronal progenitor cells (hiPS-hONPs). The therapy is designed to replace damaged or missing auditory neurons in the cochlea, aiming to restore the neural connection between the ear and the brain. Unlike Rincell-1, which targets the replacement of auditory hair cells, Rincell-2 specifically targets the auditory nerve. It is currently in the preclinical stage of development.

Other names: Rincell 2Rincell2Rincell-2Rincell-2: Auditory Neuron (hiPS-hONPs)

Beyond the preview

Go deeper on Rincell-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rincell-2.

Explore the full profile